Cargando…

Evolutionary reversion in tumorigenesis

Cells forming malignant tumors are distinguished from those forming normal tissues based on several features: accelerated/dysregulated cell division, disruption of physiologic apoptosis, maturation/differentiation arrest, loss of polarity, and invasive potential. Among them, accelerated cell divisio...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagahata, Yosuke, Kawamoto, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10662060/
https://www.ncbi.nlm.nih.gov/pubmed/38023242
http://dx.doi.org/10.3389/fonc.2023.1282417
_version_ 1785138123225694208
author Nagahata, Yosuke
Kawamoto, Hiroshi
author_facet Nagahata, Yosuke
Kawamoto, Hiroshi
author_sort Nagahata, Yosuke
collection PubMed
description Cells forming malignant tumors are distinguished from those forming normal tissues based on several features: accelerated/dysregulated cell division, disruption of physiologic apoptosis, maturation/differentiation arrest, loss of polarity, and invasive potential. Among them, accelerated cell division and differentiation arrest make tumor cells similar to stem/progenitor cells, and this is why tumorigenesis is often regarded as developmental reversion. Here, in addition to developmental reversion, we propose another insight into tumorigenesis from a phylogeny viewpoint. Based on the finding that tumor cells also share some features with unicellular organisms, we propose that tumorigenesis can be regarded as “evolutionary reversion”. Recent advances in sequencing technologies and the ability to identify gene homologous have made it possible to perform comprehensive cross-species transcriptome comparisons and, in our recent study, we found that leukemic cells resulting from a polycomb dysfunction transcriptionally resemble unicellular organisms. Analyzing tumorigenesis from the viewpoint of phylogeny should reveal new aspects of tumorigenesis in the near future, and contribute to overcoming malignant tumors by developing new therapies.
format Online
Article
Text
id pubmed-10662060
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-106620602023-01-01 Evolutionary reversion in tumorigenesis Nagahata, Yosuke Kawamoto, Hiroshi Front Oncol Oncology Cells forming malignant tumors are distinguished from those forming normal tissues based on several features: accelerated/dysregulated cell division, disruption of physiologic apoptosis, maturation/differentiation arrest, loss of polarity, and invasive potential. Among them, accelerated cell division and differentiation arrest make tumor cells similar to stem/progenitor cells, and this is why tumorigenesis is often regarded as developmental reversion. Here, in addition to developmental reversion, we propose another insight into tumorigenesis from a phylogeny viewpoint. Based on the finding that tumor cells also share some features with unicellular organisms, we propose that tumorigenesis can be regarded as “evolutionary reversion”. Recent advances in sequencing technologies and the ability to identify gene homologous have made it possible to perform comprehensive cross-species transcriptome comparisons and, in our recent study, we found that leukemic cells resulting from a polycomb dysfunction transcriptionally resemble unicellular organisms. Analyzing tumorigenesis from the viewpoint of phylogeny should reveal new aspects of tumorigenesis in the near future, and contribute to overcoming malignant tumors by developing new therapies. Frontiers Media S.A. 2023-11-07 /pmc/articles/PMC10662060/ /pubmed/38023242 http://dx.doi.org/10.3389/fonc.2023.1282417 Text en Copyright © 2023 Nagahata and Kawamoto https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Nagahata, Yosuke
Kawamoto, Hiroshi
Evolutionary reversion in tumorigenesis
title Evolutionary reversion in tumorigenesis
title_full Evolutionary reversion in tumorigenesis
title_fullStr Evolutionary reversion in tumorigenesis
title_full_unstemmed Evolutionary reversion in tumorigenesis
title_short Evolutionary reversion in tumorigenesis
title_sort evolutionary reversion in tumorigenesis
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10662060/
https://www.ncbi.nlm.nih.gov/pubmed/38023242
http://dx.doi.org/10.3389/fonc.2023.1282417
work_keys_str_mv AT nagahatayosuke evolutionaryreversionintumorigenesis
AT kawamotohiroshi evolutionaryreversionintumorigenesis